Our dedication to the scientific progress is reflected in our commitment to presenting at leading academic conferences and publishing high-quality, peer-reviewed research. These publications advance our understanding of complex and debilitating conditions, decoding the intricate web of biological process involved in an effort to pave the way for new treatment options.
March 22-25 | Banff Springs, Canada
In Alzheimer’s Subjects, Bezisterim Modulates Age-Accelerating Epigenetics in Genes Associated With Sustaining Inflammation via Kinase Cascades, Chromatin Remodeling, and Transcription Factors
February 18-22, 2026 | Bonita Springs, Florida
Bezisterim-associated anti-inflammatory epigenetic modulations of age acceleration and cognition in Alzheimer’s Disease
October 22–23, 2025 | Boston
Epigenetic modulation of age acceleration and Alzheimer’s disease genes associated with bezisterim
anti-inflammatory treatment
July 14-15, 2025 | Rome
Bezisterim Decreases Biological Age Acceleration in Alzheimer’s Disease
July 09- 10, 2025 | Vienna, Austria
Bezisterim Epigenetic Effects on Aging and Neurodegeneration
May 2, 2025
An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild- to-moderate probable Alzheimer’s disease.
August 26-30, 2024 | Copenhagen, Denmark
Bezisterim Effects on Biological Age, Alzheimer’s Epigenetics, and Neurologic Assessments
June 21-25, 2024 | Washington, D.C.
Improvement of Motor and Non-Motor Symptoms with bezisterim (NE3107) Adjunctive to carbidopa/levodopa in Patients with Parkinson’s disease: A Phase 2A, Placebo-Controlled Study
Assessment of bezisterim (NE3107) in Patients with Early Parkinson’s disease: A Phase 2, Placebo-Controlled, Hybrid Decentrallized Study
May 19-22, 2024 | Lisbon, Portugal
Improvement of Motor and Non-Motor Symptoms with Bezisterim Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s disease: A Phase 2A, Placebo-Controlled Study
April 23-25, 2024 | Boston, Massachusetts
Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s disease
Clinical Outcomes and Biomarker Findings from a Randomized, Placebo-Controlled Trial of Bezisterim in Subjects with Mild to Moderate Probable Alzheimer’s disease
March 5-9, 2024 | Lisbon, Portugal
Clinical Outcomes from a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects with Mild to Moderate Probable Alzheimer’s disease
Improvements of Non-Motor Symptoms with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s disease: A Phase 2a, Placebo-Controlled Study
November 10-14, 2023 | Boston, MA
Safety and Tolerability of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study
October 24 – 27, 2023 | Boston, MA
Oral Presentation: Clinical Outcomes From a Phase 3, Randomized, Placebo-Controlled Trial of NE3107 in Subjects With Mild to Moderate Probable Alzheimer’s disease
September 11-13, 2023 | Philadelphia, PA
Metabolic Dysregulation in Probable Alzheimer’s disease
August 27-31, 2023 | Copenhagen, Denmark
Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s disease in a Marmoset Monkey Model
Oral Presentation: Effects of NE3107 Anti-inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s disease in a Marmoset Monkey Model
Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-TreatedPatients With Parkinson’s disease: A Phase 2a, Double-Blind, Placebo-Controlled Study
A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial With NE3107 Adjunctive to Carbidopa/Levodopa in Patients With Parkinson’s disease
July 16-20, 2023 | Amsterdam, Netherlands
Treatment-Induced Epigenetic Modifications in MCI and Probable Alzheimer’s disease
June 23-26, 2023 | San Diego, CA
Metabolic Dysregulation in Probable Alzheimer’s disease
Metabolic Dysregultion in Probable Alzheimer’s disease
June 21-24 | Vienna, Austria
Safety and Efficacy of Continuous Infusion Terlipressin (BIV201) in Patients With Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study
May 13-16, 2023 | Chicago, IL
Rationale for a Potentially Pivotal Study of NE3107 in Parkinson’s disease
April 27-29, 2023 | San Diego, CA
Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias
Effects of NE3107 on Depression and Multi-modal Outcomes in a Phase 2, Open-label Study in Patients With Cognitive Decline Due to Degenerative Dementias
April 22 – 27, 2023 | Boston, MA
Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s disease
Multi-Modal Correlation Analyses From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline
Due to Degenerative Dementias
Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
March 28 – April 2, 2023 | Gothenburg, Sweden
Effect of NE3107 on the Pharmacokinetics Profile of Carbidopa/Levodopa in Patients With Parkinson’s disease: A Phase 2, Double-Blind, Placebo-Controlled Study
Safety, Tolerability, and Efficacy of NE3107 From a Phase 2, Double-Blind, Placebo-Controlled Study in Levodopa/Carbidopa-Treated Patients With Parkinson’s disease
November 29 – December 2, 2022 | San Francisco, California
Clinical Outcomes From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Biomarker Assessments From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
Neuroimaging Data From a Phase 2, Open-Label Study of NE3107 in Patients With Cognitive Decline Due to Degenerative Dementias
